The combination of HER2‐targeted therapy with PD‐1/PD‐L1 inhibitors has demonstrated synergistic effects in cancer treatment, primarily due to their combined modulation of the immune microenvironment and tumor cells. Here, ERBB2 is linked to neoplasm.